Clinical characteristics and treatment of varicella zoster virus central nervous system infection in an Australian tertiary hospital
- PMID: 40256913
- PMCID: PMC12240020
- DOI: 10.1111/imj.70076
Clinical characteristics and treatment of varicella zoster virus central nervous system infection in an Australian tertiary hospital
Abstract
Background and aim: Varicella zoster virus (VZV) is a neurotropic herpesvirus. With improved access to molecular diagnostics, there is increasing recognition of VZV with central nervous system involvement. This study aimed to describe the demographic, clinical and treatment characteristics of patients admitted to an Australian tertiary hospital with VZV central nervous system infection.
Methods: Retrospective study of all adult patients (aged ≥18 years) presenting to an Australian tertiary hospital between November 2010 and May 2023 with a clinical syndrome of or imaging consistent with meningitis or encephalitis and detectable VZV DNA in cerebrospinal fluid using polymerase chain reaction.
Results: There were 48 cases of VZV meningitis and 13 cases of VZV encephalitis identified during the study period. The median age of patients with VZV meningitis and encephalitis was 34 years (range 21-86 years) and 73 years (range 22-94 years) respectively. All patients with VZV encephalitis and 37 of 48 (77.1%) with meningitis received intravenous (IV) acyclovir. Eight patients with VZV meningitis were treated with oral antivirals alone and seven were managed without antivirals or with ≤48 h of empiric antiviral therapy only; none of these patients experienced an adverse clinical outcome. Two patients with VZV encephalitis died. Seven patients experienced neurological complications, three with VZV meningitis and four with VZV encephalitis. Age and length of stay were associated with adverse clinical outcomes.
Conclusion: VZV encephalitis predominates in older patients while VZV meningitis predominates in younger patients. IV acyclovir remains the standard of care for treatment of VZV encephalitis; however, its role in VZV meningitis is less clear. Controlled trials should be conducted to inform its use, particularly in low-risk patients with VZV meningitis.
Keywords: antiviral therapy; central nervous system infection; varicella zoster virus; viral encephalitis; viral meningitis.
© 2025 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Similar articles
-
Atypical varicella zoster virus CNS infections: Diagnostic challenges and the role of multiplex PCR.Diagn Microbiol Infect Dis. 2025 Oct;113(2):116893. doi: 10.1016/j.diagmicrobio.2025.116893. Epub 2025 May 10. Diagn Microbiol Infect Dis. 2025. PMID: 40403395
-
Characteristics of meningitis/encephalitis in adult patients with varicella-zoster virus infection: Experience from tertiary centers in Saga prefecture, Japan.J Neurol Sci. 2025 Aug 15;475:123559. doi: 10.1016/j.jns.2025.123559. Epub 2025 May 26. J Neurol Sci. 2025. PMID: 40505351
-
Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007-2014).J Neurovirol. 2017 Jun;23(3):451-459. doi: 10.1007/s13365-017-0519-y. Epub 2017 Feb 21. J Neurovirol. 2017. PMID: 28224485
-
Coinfections with monkeypox virus and varicella-zoster virus: a systematic review of case reports and case series.Arch Virol. 2025 Jul 18;170(8):183. doi: 10.1007/s00705-025-06359-6. Arch Virol. 2025. PMID: 40681794 Review.
-
Antiviral agents for infectious mononucleosis (glandular fever).Cochrane Database Syst Rev. 2016 Dec 8;12(12):CD011487. doi: 10.1002/14651858.CD011487.pub2. Cochrane Database Syst Rev. 2016. PMID: 27933614 Free PMC article.
References
-
- Parkes‐Smith J, Chaudhuri A. Varicella zoster virus: an under‐recognised cause of central nervous system infections? Intern Med J 2022; 52: 100–104. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources